Diaper dermatitis is a common cutaneous disorder in neonates and infants, which is caused by chemical irritants,
maceration, zinc deficiency and microorganisms. This study aimed to compare the therapeutic effects of three
commercial products (Nystatin, Clotrimazole and Mupirocin) in infants suffering from diaper dermititis. This singlecenter,
randomized controlled study was carried out in Iran. A total of 112 infants were included in this trial and
assigned to 3 experimental groups (Clotrimazole, Nystatin and Mupirocin) and 1 control group (zinc oxide). Survey
participants underwent a designed treatment programs for 7 days. Total symptom score after 7 days (TSS-7) and
beginning of recovery were assessed as efficacy parameters. All statistical analyses were conducted using Statistical
Package for Social Sciences (SPSS), version 19. Although the severity of diaper dermatitis was significantly
decreased in all groups by the end of trial (P <0.001), the reduction rate was found to be considerably greater in
the Clotrimazole (2.54±0.58 to 0.75±0.65) and Mupirocin (2.17±0.71 to 1.00±0.91), respectively. In addition, time
required for first response was significantly lower in Mupirocin, in comparison with the other medications.
Clotrimazole and Mupirocin were superior to others with respect to reduction of symptom score and time of
recovery, respectively. Therefore, it is important to determine the etiology of skin distruption and priorities of
treatment to apply the best therapeutical approach.
Keywords: Diaper dermatitis, Clotrimazole, Nystatin, Mupirocin